Bronchopulmonary effects of endothelin.
Explore the source record for details and available documents.
Animals↗
Biomedical subjects
V Lagente
Publications and source records attributed to V Lagente.
Failure of aerosolized endothelin (ET-1) to induce bronchial hyperreactivity in the guinea pig.
Aerosol administration of endothelin (ET-1) has been shown to provoke a potent bronchoconstriction in the guinea pig. We investigated whether or not, aerosolized ET-1 induces a bronchial hyperreactivity in the guinea pig. Aerosolized ET-1 (10 micrograms/ml for 60 min) did not alter the dose-response curve, established by successive aerosol administration of acetylcholine (ACh) 3-4 h and 18-24 h after challenge with the peptide. In a second protocol, aerosolized ET-1 (10 micrograms/ml for 3 min) induced, in anaesthetized guinea pigs a bronchopulmonary response but did not alter the dose-response curve to aerosolized ACh established 30 min after the challenge. These results suggest that ET-1 may participate to the early, but not the late alteration of the bronchopulmonary tone observed during pathophysiological conditions.
Acetylcholine↗
Contractile activity of three endothelins (ET-1, ET-2 and ET-3) on the human isolated bronchus.
1. The effects of three endothelins: (i) the classical or human/porcine endothelin (ET-1); (ii) [Trp6, Leu7] endothelin (ET-2) and (iii) [Thr2, Phe4, Thr5, Tyr6, Lys7, Tyr14] endothelin or rat endothelin (ET-3) were tested on the human isolated bronchus. 2. ET-1 produced a concentration-dependent contraction of the human isolated bronchus that proceeded in two different steps. The first step was observed at very low concentrations (pD2 = 11.01 +/- 0.17, n = 10) but corresponded to a low intrinsic activity (Emax = 15.6 +/- 1.8% of Emax = 26.1 +/- 2.9% of ACh 3 x 10(-3) M, n = 5, P less than 0.05), reduced by nicardipine 10(-6) M (Emax = 6.0 +/- 2.6% of ACh 3 x 10(-3) M, n = 5, P less than 0.05) and strongly inhibited in calcium-free medium. The second step of the action of ET-1 corresponded to a lesser potency (pD2 = 7.90 +/- 0.17, n = 9) but a higher intrinsic activity (Emax = 82.5 +/- 4.7% of ACh 3 x 10(-3) M). This effect was not significantly modified by nicardipine 10(-6) M or by Bay K 8644 10(-7) M. Neither of the two effects was modified by indomethacin 3 x 10(-6) M. 3. The effects of ET-2 and ET-3 were qualitatively similar to those of ET-1 but quantitatively different; for these two steps of contracting activity and for potency and efficacy the ranking was: ET-1 greater than ET-2 = ET-3. 4. Thus, ET-1 appears to be the most potent of these three substances in its effect on the human isolated bronchus. Its activity seems to involve the action of voltage-dependent calcium channels at low concentrations (10-12 to 10-9M), whereas other mechanisms are involved at higher concentrations (10-8 to 3 x 10-7M).
3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethy↗
Pharmacological modulation of the bronchopulmonary action of the vasoactive peptide, endothelin, administered by aerosol in the guinea-pig.
Administration by aerosol for 1 min of solutions of endothelin (ENDO; 1, 5 or 10 micrograms/ml) to anaesthetized and ventilated guinea-pigs induced a dose-dependent bronchopulmonary response (BR) which was maximal within 4 to 5 min. In contrast, no significant change of the mean arterial blood pressure was observed. Pretreatment of guinea-pigs with propranolol (1 mg/kg, i.v.), mepyramine (1 mg/kg, i.v.), nifedipine (50 mg/kg, i.p.) or verapamil (0.3 mg/kg, i.v.) did not significantly affect the BR induced by an aerosol of a solution of 10 micrograms/ml ENDO. In contrast, BR was significantly reduced when the animals were pretreated with the cyclooxygenase inhibitor, indomethacin (10 mg/kg, i.v.) or the platelet-activating factor (PAF) receptor antagonist, BN 52021 (10 mg/kg, i.v.). These results indicate that aerosolized ENDO induces a BR via the generation of secondary mediators such as cyclooxygenase products and PAF in a process which is unaffected by the blockers of the voltage-dependent calcium channels.
Aerosols↗
Effect of endothelin-1 on blood pressure and bronchopulmonary system of the guinea pig.
The bronchopulmonary and pressor effects of endothelin-1 (ET-1), a newly described vasoconstrictor peptide produced by endothelial cells, were investigated in the guinea pig. Intravenous injection of ET-1 (1 nmol/kg) induced an increase in pulmonary inflation pressure (PIP) as well as an important and sustained increase in arterial blood pressure (BP). Pretreatment of these animals with propranolol (1 mg/kg i.v.), provoked a significant enhancement of the ET-1-induced increase in PIP, accompanied by a dramatic and significant decrease of BP. When administered by aerosol for 1 min, ET-1 (1, 5, or 10 micrograms/ml) induced a dose-dependent increase in PIP that was maximal by 4-5 min, but no significant change of BP. Pretreatment of guinea pigs with propranolol (1 mg/kg), mepyramine (1 mg/kg i.v.), nifedipine (50 mg/kg i.p.), or verapamil (0.3 mg/kg i.v.) did not inhibit the bronchopulmonary response evoked by aerosol administration of 10 micrograms/ml of ET-1. In contrast, pretreatment of the animals with indomethacin (10 mg/kg i.v.) or BN 52021 (10 mg/kg i.v.) significantly reduced the bronchopulmonary response of ET-1 given by aerosol. Injection of ET-1 (0.1, 0.3, and 1 micrograms) into isolated guinea pig lungs caused significant increases in PIP that were accompanied by the release of TxB2 but not histamine. These results demonstrate that ET-1 induces bronchopulmonary alterations in the guinea pig that appear to be dissociated from the systemic vascular effects of the peptide.
Animals↗
Interference of the Paf antagonist Ro 19-3704 with Paf and antigen-induced bronchoconstriction in the guinea-pig.
1. In vitro, Ro 19-3704, a structurally related antagonist of platelet-activating factor (Paf) inhibited selectively rabbit platelet aggregation. In vivo, administered intravenously, it inhibited bronchoconstriction, leukopenia, thrombocytopenia and the accompanying accumulation of platelet aggregates in guinea-pig lung microvessels induced by i.v. Paf. Administered by aerosol, Ro 19-3704 failed to inhibit bronchoconstriction, thrombocytopenia or leukopenia due to i.v. Paf. 2. Bronchoconstriction induced by Paf, in aerosol form, was blocked by Ro 19-3704 administered by the i.v. or aerosol route, which suggests that it interacts with pulmonary cells responsible for bronchoconstriction. 3. Ro 19-3704 has free radical scavenging properties, since it inhibited the production of superoxide anions by macrophages stimulated by Paf and by N-formyl-methionyl-leucyl-phenylalanine (FMLP). Ro 18-7715, another Paf antagonist and analogue of Ro 19-3704, failed to inhibit the production of superoxide anions by macrophages stimulated by FMLP at concentrations which were effective against Paf. 4. Administered intravenously, Ro 19-3704 failed to block bronchoconstriction induced by an i.v. injection of ovalbumin to guinea-pigs passively sensitized with anti-ovalbumin antiserum. Passive pulmonary anaphylaxis due to an aerosol of ovalbumin was blocked by i.v. Ro 19-3704.
Aerosols↗
Involvement of PAF-acether in anaphylactic bronchoconstriction induced in guinea pigs by aerosolized antigen.
Bronchoconstriction following the aerosolization of PAF-acether or antigen to guinea pigs induces autodesensitization, but the responses to direct spasmogenic substances are not modified. Bronchoconstriction by PAF-acether is not reduced when it is aerosolized to passively sensitized animals previously desensitized by repeated inhalations of the allergen (ovalbumin). In contrast, when passively sensitized animals are initially desensitized to PAF-acether by repeated inhalations of this agonist, ovalbumin aerosolization induces a bronchoconstriction which is significantly reduced when compared with the response obtained in nondesensitized animals though, in this case, the response to aerosolized histamine is not modified. Thus, PAF-acether is released during intrapulmonary anaphylactic shock induced by aerosolized ovalbumin and can be a prime candidate for its development.
Aerosols↗
Role of PAF-acether in the vascular events of inflammation.
Explore the source record for details and available documents.
Capillary Permeability↗
PAF-acether and endotoxin display similar effects on rat mesenteric microvessels: inhibition by specific antagonists.
The activity of platelet activating factor (PAF-acether) and the effects of specific antagonists BN 52021 and WEB 2086 on microvessels were studied. The mesentery of anaesthetized male Wistar rats was exteriorized and arranged for microscopic observation of the microcirculation in situ. Vessel diameters were measured with an image splitting micrometer adjusted to the phototube of the microscope. Images were displayed on the monitor screen of a closed-circuit television system. Topical application of PAF (10, 100 and 200 microM) enlarged the diameter of mesenteric arterioles and venules, which was antagonized by PAF antagonists administered i.v. (1 mg/kg) or topically (10 microM). Bolus injection (1 micrograms/kg) or perfusion (100 ng/kg/min) of PAF significantly decreased mean arterial blood pressure of the animals and slightly increased arteriolar diameters. These effects were blocked by the PAF antagonists. Endotoxin (10-20 mg/kg i.v.) significantly enlarged arteriolar diameters and produced a significant drop of arterial blood pressure. These effects were blocked by the PAF antagonists at doses equivalent to those used to antagonize the effects of PAF. The leukocyte activator fMLP, as well as lyso-PAF and PAF antagonists, were devoid of effects on the microcirculation when applied topically or injected i.v. We conclude that mesenteric microvessels contribute to the hypotensive effect of PAF and endotoxin and that PAF is released at the mesenteric area during endotoxic shock.
Animals↗
Evidence for platelet-activating factor as a mediator of endotoxin-induced gastrointestinal damage in the rat. Effects of three platelet-activating factor antagonists.
The potential role of platelet-activating factor (PAF) as a mediator of gastrointestinal ulceration associated with septic shock was examined in the rat. The damaging effects of both PAF and Escherichia coli endotoxin in the stomach and small intestine were compared, as were their effects on plasma leakage into the lumen of the gastrointestinal tract. Intravenous administration of either endotoxin or PAF produced extensive necrosis and vascular congestion in the stomach and small intestine, but not the distal colon. With either agent, the duodenum and jejunum were the tissues most susceptible to damage and in which the greatest plasma leakage was observed. The prolonged hypotension and gastrointestinal damage induced by PAF or endotoxin were significantly inhibited by three structurally dissimilar PAF antagonists (CV-3988, BN-52021, and Ro-193704). CV-3988 (10 mg/kg) significantly (p less than 0.05) reduced both endotoxin- and PAF-induced plasma leakage in the stomach and small intestine. Of the three antagonists, only CV-3988 significantly reduced ethanol-induced gastric mucosal damage, perhaps reflecting actions of this compound unrelated to antagonism of PAF receptors. These studies support the hypothesis that PAF is an important mediator of the hypotension and plasma leakage observed during endotoxic shock and its endogenous release may contribute to the gastrointestinal ulceration associated with this syndrome. Thus, PAF receptor antagonists may be useful for prevention of such ulceration.
Animals↗
Interference of the PAF-acether antagonist BN 52021 with passive anaphylaxis in the guinea-pig.
PAF-acether may be involved in anaphylaxis and asthma. We tested the new PAF-acether antagonist BN 52021 against the effects of antigen in passively sensitized guinea-pigs. Bronchoconstriction by ovalbumin administered i.v. (1 mg/kg) or by aerosol (1 or 10 mg/ml for a period of 1 min) was significantly reduced by BN 52021 (1-10 mg/kg), which did not inhibit drop of leukocyte counts after the i.v. challenge. In both cases, when the guinea-pigs were pretreated by propranolol, high amounts of BN 52021 became ineffective against shock. The reduction of the anaphylactic bronchoconstriction, induced by the combination of mepyramine, aspirin and FPL 55712 was not improved by BN 52021. Tested on isolated lung strips from passively sensitized guinea-pig, BN 52021, at a concentration which inhibits PAF-induced contraction (0.1 mM), did not inhibit the anaphylactic contraction triggered by the administration of ovalbumin (10 micrograms/ml) nor the accompanying release of histamine and thromboxane. In contrast, BN 52021 (30 microM) significantly reduced the anaphylactic release of histamine and of thromboxane from perfused lungs of passively sensitized guinea-pigs. The results with the isolated lung strips and the propranolol-treated guinea-pigs in vivo suggest a dissociation between the anti-anaphylactic and the anti-PAF-acether properties of BN 52021.
Airway Resistance↗
Interference of the PAF-acether antagonist BN 52021 with anaphylaxis in the guinea pig.
Explore the source record for details and available documents.
Anaphylaxis↗
Platelet-activating factor (PAF-acether) and microcirculation: effect of Lyso-PAF and PAF-antagonists.
Topical application of a standard dose of noradrenaline (NA) to the anesthetized rat mesentery evoked a vasoconstrictor response the latency of which was increased in a dose-dependent way by previous addition of PAF-acether or histamine but not by Lyso-PAF. Lyso-PAF, however, blocked the antagonistic effect of PAF-acether to NA, the blockade being equivalent to that observed with PAF-antagonists (BN 52021 or WEB 2086) either injected iv, or applied topically. In contrast, the antagonistic action of histamine towards NA was not affected by Lyso-PAF or PAF-antagonists. Since platelet aggregation and leukocyte accumulation did not occur, PAF-acether appears to interact directly with microvessels to block vasoconstrictor stimuli, an effect antagonized by PAF-antagonists and the metabolite/precursor, Lyso-PAF.
Animals↗
Interference of BN 52021 (ginkgolide B) with the bronchopulmonary effects of PAF-acether in the guinea-pig.
The interaction between the ginkgolide BN 52021 and the effects of PAF-acether on the bronchopulmonary system of the guinea-pig was studied. In pentobarbitone or ethyl carbamate-anaesthetized animals, BN 52021 (1 mg/kg i.v. or 10 mg/kg p.o.) inhibited bronchoconstriction, the hematocrit increase and the accompanying thrombopenia and leukopenia induced by PAF-acether (33-100 ng/kg) and failed to block the bronchoconstriction produced by collagen, arachidonic acid and the tripeptide formyl-Met-Leu-Phe (FMLP). BN 52021, 3 mg/kg, reduced the bronchoconstriction induced by aerosolized PAF-acether. BN 52021, 300 microM, also inhibited the superoxide production by PAF-acether-stimulated alveolar macrophages and failed to reduce the same effects when triggered by FMLP (0.01-1 microM). BN 52021 blocked the formation of thromboxane-triggered by PAF-acether (100 ng) injected into perfused lung, under conditions where the effects of arachidonic acid where not modified. Finally, pretreatment of parenchyma lung strips with BN 52021 (100 microM) partially inhibited the contraction induced by PAF-acether (0.1 microM) and suppressed the accompanying release of thromboxane. BN 52021 is a selective antagonist of the effects of PAF-acether on the bronchopulmonary system and on circulating blood cells of the guinea-pig.
Animals↗
Pharmacological modulation of the respiratory and haematological changes accompanying active anaphylaxis in the guinea-pig.
The intrathoracic accumulation of radiolabelled platelets was recorded in anaesthesized, sensitized guinea-pigs concomitantly with changes in airways resistance during active anaphylaxis. Antigen challenge induced an increased airway resistance associated with intrathoracic platelet accumulation, thrombocytopenia and leukopenia. Bronchoconstriction, but not the haematological changes, was modified by a combination of mepyramine, methysergide and aspirin. The addition of FPL 55712 and PGI2 to this cocktail of drugs additionally inhibited the thrombocytopenia and leukopenia but not the intrathoracic accumulation of platelets induced by antigen challenge. PGI2 was alone able to significantly inhibit the intrathoracic platelet accumulation, but not the bronchoconstriction induced by antigen challenge. These results suggest that active anaphylaxis is associated with activation of blood elements and subsequent pulmonary entrapment of platelets but that the platelet release reaction rather than the embolisation of platelet aggregates is the critical step in the induction of allergic bronchoconstriction in the guinea-pig.
Airway Resistance↗
Pharmacological control of the in vivo passive anaphylactic shock by the PAF-acether antagonist compound BN 52021.
BN 52021 antagonized PAF-acether-induced bronchoconstriction (BC) in the guinea-pig and inhibited BC triggered by antigen in passively sensitized animals. The anti-anaphylactic activity was prevented by propranolol and may either result from an additional property of the drug, independent from PAF antagonism or from different PAF-dependent mechanisms with different responsiveness to the various antagonists.
Anaphylaxis↗
Interference of BN 52021, a PAF-acether antagonist, with endotoxin-induced hypotension in the guinea-pig.
Explore the source record for details and available documents.
Animals↗
A study with BN 52021 demonstrates the involvement of PAF-acether in IgE-dependent anaphylactic bronchoconstriction.
The involvement of platelet activating factor (PAF) in anaphylaxis was examined by recording the pulmonary responses of anesthetized passively sensitized guinea-pigs to the aerosolization of ovalbumin. Animals were tested with and without BN 52021 (a ginkgolide B, PAF receptor antagonist) pretreatment. Aerosolization of ovalbumin produced a bronchoconstriction (BC) which could be made refractory to additional challenges with the antigen. In animals desensitized to ovalbumin, aerosolization of PAF produced an unattenuated BC. Guinea pigs desensitized by repeated aerosolizations of PAF subsequently showed reduced responses to aerosolized antigen suggesting that PAF may be involved in the BC. Animals pretreated with BN 52021, were protected against the effects of systemically administered PAF and also showed reduced responses to aerosolized antigen. Aerosolization of the leukotriene antagonist, FPL 55712, was ineffective against anaphylactic BC under conditions where catecholamine and histamine release were blocked.
Aerosols↗